Effect of Oat in patients with Non alcoholic fatty liver disease

The effect of oat consumption on hepatic and blood glucose control indices and lipid profile in patients with non-alcoholic fatty liver

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130903014551N12

Enrollment

Registered

2023-01-18

Start date

2023-05-05

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Nonalcoholic fatty liver disease

Interventions

Intervention 1: Intervention group: For 12 weeks, 50 grams of oat powder should be consumed twice a day (25 grams) with 1 glass of water, milk, and dough. The time to consume oats is morning and even

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Grade 2,3,4 non alcoholic fatty liver disease by ultrasound The level of liver enzymes should be between normal up to 2 times than average level A person should not consume alcohol or use less than 30 grams for men and 20 grams for women Absence of pregnancy and breastfeeding Absence of liver cirrhosis Not following a special diet Absence of malignancy and underlying diseases Not taking insulin in diabetic patients BMI should be between 25-40 kg/m²

Exclusion criteria

Exclusion criteria: Reluctance to consume oats Starting a new drug or changing the dose of previous drugs related to fatty liver in the last two months

Design outcomes

Primary

Measure	Time frame
Alanine amino transferase (ALT). Timepoint: Measuring alanine aminotransferase before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Aspartate aminotransferase. Timepoint: Measuring aspartate aminotransferase before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Fasting blood glucose (FBS). Timepoint: Measuring fasting blood glucose before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Insulin. Timepoint: Measuring Insulin before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Total Cholesterol. Timepoint: Measuring total Cholesterol before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Low density lipoprotein (LDL). Timepoint: Measuring LDL before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;High density lipoprotein (HDL). Timepoint: Measuring HDL before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Triglyceride (TG). Timepoint: Measuring TG before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Quantitative Insulin Sensitivity Check Index (QUICKI). Timepoint: Measuring(QUICKI) before the intervention and At the end of the twelfth week. Method of measurement: QUIKI = 1 / [log fasting insulin (FI) + log fasting glucose (FG)].;Homeostasis Model Assessment Insulin Resistance (HOMA-IR). Timepoint: Measuring (HOMA-IR) before the intervention and At the end of the twelfth week. Method of measurement: HOMA-IR = fasting insulin (µU/L) x fasting glucose (nmol/L)/22.5.	—

Measure

Time frame

Alanine amino transferase (ALT). Timepoint: Measuring alanine aminotransferase before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Aspartate aminotransferase. Timepoint: Measuring aspartate aminotransferase before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Fasting blood glucose (FBS). Timepoint: Measuring fasting blood glucose before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Insulin. Timepoint: Measuring Insulin before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Total Cholesterol. Timepoint: Measuring total Cholesterol before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Low density lipoprotein (LDL). Timepoint: Measuring LDL before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;High density lipoprotein (HDL). Timepoint: Measuring HDL before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Triglyceride (TG). Timepoint: Measuring TG before the intervention and At the end of the twelfth week. Method of measurement: Blood sample and autoanalyzer.;Quantitative Insulin Sensitivity Check Index (QUICKI). Timepoint: Measuring(QUICKI) before the intervention and At the end of the twelfth week. Method of measurement: QUIKI = 1 / [log fasting insulin (FI) + log fasting glucose (FG)].;Homeostasis Model Assessment Insulin Resistance (HOMA-IR). Timepoint: Measuring (HOMA-IR) before the intervention and At the end of the twelfth week. Method of measurement: HOMA-IR = fasting insulin (µU/L) x fasting glucose (nmol/L)/22.5.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hossein Rouhani

Esfahan University of Medical Sciences

s_m_rouhani2003@yahoo.com+98 31 3792 3183

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026